Amalgamated Bank Has $62,000 Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Amalgamated Bank lifted its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 26.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,887 shares of the biopharmaceutical company’s stock after buying an additional 1,036 shares during the period. Amalgamated Bank’s holdings in Novavax were worth $62,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Shah Capital Management increased its stake in shares of Novavax by 4.3% during the 1st quarter. Shah Capital Management now owns 8,117,827 shares of the biopharmaceutical company’s stock worth $38,803,000 after purchasing an additional 337,071 shares during the last quarter. Rafferty Asset Management LLC increased its stake in shares of Novavax by 62.4% during the 4th quarter. Rafferty Asset Management LLC now owns 1,611,840 shares of the biopharmaceutical company’s stock worth $7,737,000 after purchasing an additional 619,370 shares during the last quarter. Coatue Management LLC acquired a new position in shares of Novavax during the 4th quarter worth $7,294,000. TSP Capital Management Group LLC grew its stake in Novavax by 23.9% in the 1st quarter. TSP Capital Management Group LLC now owns 1,376,950 shares of the biopharmaceutical company’s stock valued at $6,582,000 after buying an additional 265,250 shares during the last quarter. Finally, Farallon Capital Management LLC acquired a new position in Novavax in the 1st quarter valued at $5,406,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Monday, August 12th. B. Riley restated a “buy” rating and set a $23.00 target price (down previously from $25.00) on shares of Novavax in a research note on Monday, August 12th. Finally, Bank of America lifted their price target on Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, June 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Novavax has a consensus rating of “Hold” and an average price target of $15.80.

Novavax Stock Down 2.5 %

Shares of NVAX opened at $12.32 on Wednesday. The stock’s 50-day moving average price is $12.71 and its 200 day moving average price is $11.04. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -3.89 and a beta of 2.04.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million during the quarter, compared to analyst estimates of $458.57 million. During the same period last year, the firm earned $0.58 EPS. The company’s quarterly revenue was down 2.1% compared to the same quarter last year. Equities research analysts expect that Novavax, Inc. will post -1.04 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.